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Abstract
Background: After unilateral cervical cord lesion at the C7/C8 border interrupting the dorsolateral
funiculus in adult monkeys, neutralization of Nogo-A using a specific monoclonal antibody promoted
sprouting of corticospinal (CS) axons rostral and caudal to the lesion and, in parallel, improved functional
recovery. In monkeys lesioned but not treated with the anti-Nogo-A antibody, the CS neurons in the
contralesional primary motor cortex (M1) survived to the axotomy, but their soma shrank. Because the
anti-Nogo-A treatment induces regeneration and/or sprouting of CS axons, it may improve access to
neurotrophic factors. The question therefore arises as to whether anti-Nogo-A treatment prevents the
soma shrinkage observed in the contralesional M1?
Results: Using the marker SMI-32, a quantitative and qualitative anatomical assessment of the pyramidal
neurons in the layer V (thus including the CS cells) in M1 was performed and compared across three
groups of animals: intact monkeys (n = 5); monkeys subjected to the cervical cord lesion and treated with
a control antibody (n = 4); monkeys with the cervical lesion and treated with anti-Nogo-A antibody (n =
5). SMI-32 positive neurons on the side contralateral to the lesion were generally less well stained than
those on the ipsilesional hemisphere, suggesting that they expressed less neurofilaments. Nevertheless, in
all three groups of monkeys, the amount of SMI-32 positive neurons in both hemispheres was generally
comparable, confirming the notion that most axotomized CS neurons survived. However, shrinkage of CS
cell body area was observed in the contralesional hemisphere in the two groups of lesioned monkeys. The
cell surface shrinkage was found to be of the same magnitude in the monkeys treated with the anti-Nogo-
A antibody as in the control antibody treated monkeys.
Conclusion: The anti-Nogo-A antibody treatment did not preserve the axotomized CS cells from soma
shrinkage, indicating that the anti-Nogo-A antibody treatment affects morphologically the axotomized CS
neurons mainly at distal levels, especially the axon collateralization in the cervical cord, and little or not at
all at the level of their soma.
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Background
The motor deficits associated with interruption of the CS
tract at a segmental level in monkeys were assessed in sev-
eral studies [1-10]. More precisely, a surprisingly good
and rapid recovery of dexterous finger movements of the
ipsilateral hand took place after hemi-section at C3 level
in either newborn and juvenile monkeys [4,5], or in adult
monkeys after hemi-section at C4/C5 [8] or C7/C8 level
[9,10]. Immediately after the cervical hemi-section and
later on during the recovery, there was a dramatic reduc-
tion of the CS projection to the hemi-cord caudal to the
lesion [4], indicating that the spontaneous recovery of
manual dexterity was not due to a substantial reconstruc-
tion of the lesioned projection but rather to enhancement
of the transmission of information from cortex to spinal
cord in a reduced number of CS and/or corticobulbospi-
nal projections together with a contribution of a more
effective use of spinal circuits.
As far as the fate of the axotomized CS neurons is con-
cerned, some controversy can be found in the literature.
Some earlier anatomical studies suggested that pyrami-
dotomy [11,12] or cervical cord lesion [6,13] induced the
death of a substantial part of the large CS neurons in the
contralateral primary motor cortex (M1), amounting up
to 70% loss [11]. In sharp contrast, other authors con-
cluded that there was no retrograde degeneration with
breakdown and loss of neurons after section of the CS
tract [14-16]. In a recent study [17], the issue of the fate of
axotomized CS neurons was re-examined in two monkeys
using SMI-32 as a specific marker for pyramidal neurons.
We found that, after unilateral lesion of the dorsolateral
funiculus at cervical level (C7-C8), the CS neurons in the
contralesional primary motor cortex (M1) survived the
axotomy, but their soma shrank [17].
In a recent report, evidence was provided in monkeys that
the functional recovery from unilateral cervical cord
lesion and CS axonal sprouting can be enhanced by an
antibody treatment neutralizing the neurite growth inhib-
itor Nogo-A [10], extending to the primates previous
results obtained in the rat [18-21]. Indeed, several func-
tional readouts of manual dexterity showed a faster and
more complete recovery of manual dexterity in a group of
six anti-Nogo-A antibody treated monkeys subjected to
cervical hemi-section than in a group of six monkeys sub-
jected to a comparable lesion but treated with a control
antibody [10]. Such enhancement of manual dexterity
promoted by anti-Nogo-A antibody treatment was associ-
ated with an axonal sprouting of CS axons in the cervical
cord rostral and caudal to the lesion [10,22]. These new
fibers could provide the axotomized CS neurons an aug-
mented access to neurotrophic factors compared to that
available to the axotomized CS neurons in control anti-
body treated animals. The goal of the present study was
thus to investigate whether the anti-Nogo-A antibody
treatment also exerts an effect on the CS neurons at the
level of their soma in the contralesional motor cortex, for
instance by preventing the cell soma shrinkage occurring
in the monkeys subjected to cervical lesion and treated
with a control antibody [17]. This hypothesis is plausible
because the treatment induces regeneration and/or
sprouting of CS axons and may thus increase the access to
neurotrophic substances. Moreover, although the anti-
Nogo-A antibody was delivered intrathecally in the cervi-
cal cord close to the lesion, the antibody was shown to
reach the entire brain through the CSF circulation [23]
and, therefore, it may have affected the CS cell bodies in
the cerebral cortex as well.
Results
Cervical cord lesion
For the animals subjected to the unilateral spinal cord sec-
tion, the extent of the lesion was assessed by reconstruct-
ing the incision site from histological sections (Fig. 1A). In
most monkeys, the lesion completely transected the dor-
solateral funiculus, thus corresponding to a complete
transection of the CS axons originating from the contrale-
sional hemisphere (as checked with BDA labeling of CS
axons in most monkeys [10]). In one monkey (asterisk in
Fig. 1A), the dorsolateral funiculus was not completely
transected and therefore a few CS axons as well as RS
axons were spared by the lesion. The other seven monkeys
had a complete transection of the dorsolateral funiculus
on the lesioned hemi-cord (Table 1), thus corresponding
to a complete interruption of the main CS tract originat-
ing from the opposite hemisphere (as discussed in detail
earlier in [10]). The monkeys Mk-AF and Mk-CC clearly
had an incomplete lesion of the RS tract, whereas mon-
keys Mk-CS and Mk-CB possibly had an incomplete
lesion of the RS tract (though transected at 95% at least).
The RS tract transection was complete in the other four
monkeys with complete lesion of the dorsolateral funicu-
lus (Mk-AG, Mk-AC, Mk-AM and Mk-CH).
Do some axotomized CS neurons degenerate?
In a recent paper, we reported that the number of SMI-32
positive pyramidal neurons in layer V in M1 was compa-
rable in the contralesional and in the ipsilesional hemi-
spheres in two monkeys subjected to an unilateral cervical
lesion (treated with a control antibody), and amounted to
a comparable figure as in two intact animals [17]. In the
present study, these data were extended to a total of four
monkeys subjected to the cervical lesion (treated with a
control antibody) and five intact monkeys (Fig. 1C; blue
and green bars, respectively). In the group of intact mon-
keys, as expected the majority (four out of five) of animals
did not show a statistically significant difference of SMI-
32 positive neurons between the two hemispheres (p >
0.05, n.s. in Fig. 1C). However, in one intact monkey (Mk-BMC Neuroscience 2008, 9:5 http://www.biomedcentral.com/1471-2202/9/5
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Spinal cord lesion and number of pyramidal neurons in layer V of the motor cortex Figure 1
Spinal cord lesion and number of pyramidal neurons in layer V of the motor cortex. A: Reconstruction from 
paralongitudinal sections of the lesion performed in eight monkeys at cervical level C7/C8. The lesion area is indicated in red 
for the anti-Nogo-A antibody treated monkeys and in blue for the control antibody treated monkeys. The gray zone in the 
center corresponds to the gray matter. In one monkey (Mk-AT), the tissue was damaged in the zone of the cervical cord lesion 
and it was not possible to precisely assess the position and extent of the lesion. The lesions have already been shown in recent 
reports [10,22]. Although some lesions were on the left side and others on the right side, for simplification they were all rep-
resented here as a left side lesion. B: Photomicrograph showing the part of M1 corresponding to the hindlimb representation 
on both hemispheres and stained with SMI-32. On both sides, SMI-32 typically labeled the pyramidal cells in the layers III and V. 
However, typically at such low magnification, the layer V appears more densely stained on the ipsilesional hemisphere than on 
the contralesional one (see text). The hindlimb area in M1 was thus visible on the same section for the two hemispheres and 
the observer could thus delineate roughly equally long portions of the layer V in each hemisphere on which the counts were 
performed (dashed line), as explained in detail earlier [17]. The length of the portion of layer V in which counts were made (in 
mm) was determined for data normalization. CIN = cingulate sulcus. C: Bar graph indicating the mean number of SMI-32 posi-
tive neurons per unit length (and SD) counted in layer V of the hindlimb area in M1 of each hemisphere, on the sample of sec-
tions examined in the three groups of monkeys (green is for intact monkeys). * is for p <= 0.05; n.s. is for p > 0.05 (t-test for 
small samples as explained in the methods section). D: A portion of the hindlimb area in M1, on which morphometric measure-
ments were conducted, is shown at higher magnification, for a typical contralesional hemisphere (left photomicrograph). At 
low magnification (panel B), due to lighter SMI-32 staining than in the ipsilesional hemisphere, very few SMI-32 positive neurons 
were visible in layer V. At this magnification (left photomicrograph), some SMI-32 positive neurons appear. The observer then 
identified at high magnification all SMI-32 positive neurons with a visible nucleus in layer V (neurons highlighted on top of a yel-
low background), as shown on the right photomicrograph. In general, it turned out that, in spite of a lighter SMI-32 staining, the 
positive neurons with a visible nucleus were on average as numerous as in the ipsilesional hemisphere. In each photomicro-
graph, the cortical surface is on top and the white matter on bottom. The SMI-32 positive neurons are typically found in layers 
III and V.B
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Table 1: List of cervical cord lesioned and intact monkeys included in the present study with identification code (same as in [10]).
Mk-AG Mk-AT Mk-AF Mk-AC Mk-AM Mk-CS Mk-CB Mk-CC Mk-CH Mk-IR Mk-IE Mk-IZ Mk-IRh Mk-IG
species fasc. fasc. mul. fasc. fasc. mul. fasc. fasc. fasc. mul. mul. fasc. mul. mul
Antibody Treatment Anti-Nogo-A (hNogo) Anti-NogoA (hNogo) Anti-Nogo-A 
(11C7)
Anti- Nogo-A 
(hNogo)
Anti-Nogo-A 
(hNogo)
Contr. Contr. Contr. Contr. --- - -
Hemi-section total extent (%) 78 * 56 85 80 63 75 38 90 --- - -
Completeness of dorsolateral funiculus section Yes * Yes Yes Yes Yes Yes No Yes --- - -
RS and CS lesion extent (%) 100 * 73 100 100 87 93 61 100 --- - -
Functional Recovery (%) 100 (100)* 57 100 96 22 78 83 53 --- - -
Completeness of CS/RS section Yes * No Yes Yes Yes Yes No Yes --- - -
Survival time after lesion (in days) 112 97 144 135 138 198 225 105 138 - - - - -
ICMS no no yes no no yes no yes no no no no no no
At the time of the experiment, the lesioned monkeys had different names, not indicating whether the animal was infused with the control or the anti-Nogo-A antibody, corresponding to a double blind 
procedure (except Mk-AF, Mk-CS and Mk-CC). New names were assigned to the monkeys during the writing of the manuscript to improve its readability, in consistency with [10].
Under species, "mul." is for macaca mulatta while "fasc." is for macaca fascicularis.
The five anti-Nogo-A antibody treated monkeys are in the five leftmost columns ("Anti-Nogo-A") with indication of which of the two antibodies was used (mAB11C7 or mAB hNogo-A), whereas the four 
control antibody treated monkeys ("Contr.") are in the next four columns. The five intact monkeys are in the five rightmost columns.
Total hemi-section extent was calculated as the percentage of corresponding hemi-cord affected by the lesion on the frontal reconstruction of the cervical cord.
To tentatively determine more precisely the extent of the RS and CS lesions a quadrant of the lateral funiculus in the white matter was outlined going from the dorsal to the ventral rootlet zone. This was 
indicated as RS and CS lesion extent.
Functional recovery was assessed here for manual dexterity based on the "modified Brinkman board" task (see [10]), by giving in percent the ratio of the post-lesion score to the pre-lesion score.
In the row "completeness of RS section", "No" and "Yes" indicates whether the RS transection was considered as partial or as complete, respectively (for further explanation see text).
Survival time: number of days separating the cord hemi-section from the sacrifice of the animal.
* In this animal the total hemi-section extent and consequently also the RS and CS extent could not be calculated for technical reasons (poor quality of histology). In addition in this same animal the lesion was 
too caudal and thus the 100% functional recovery cannot be interpreted.
ICMS is for intracortical microstimulation. "Yes" means that the corresponding monkeys were subjected to extensive ICMS both pre- and post-lesion in order to study the change of motor maps (somatotopy) 
in relation to the lesion (see [9, 28]).BMC Neuroscience 2008, 9:5 http://www.biomedcentral.com/1471-2202/9/5
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IU), the number of SMI-32 positive neurons per unit
length was significantly higher (p < 0.05) in the right than
in the left hemisphere (Fig. 1C), indicating that even in
intact monkeys there may be cases in which the density of
SMI-32 positive neurons in layer V of M1 differs between
the two hemispheres. Accordingly, there was also one
monkey (Mk-CS) in the group of lesioned monkeys
treated with the control antibody (blue bars in Fig. 1C)
exhibiting an inter-hemispheric difference of the number
of SMI-32 positive neurons per unit length (p < 0.05),
whereas in the other three monkeys the difference was not
statistically significant. However, still in the group of
lesioned monkeys treated with the control antibody (blue
bars in Fig. 1C), there was no systematic trend with respect
to the side of the lesion. These data thus confirm the
notion that axotomy of the crossed CS tract at cervical
level in macaque monkeys treated with a control antibody
does not lead to significant neuronal loss. As anticipated,
the same conclusion applies to the group of five monkeys
subjected to cervical cord lesion and treated with anti-
Nogo-A antibody (Fig. 1C; red bars): in two monkeys
there were slightly more SMI-32 positive neurons in the
contralesional hemisphere whereas in the other three
monkeys the ipsilesional hemisphere had more SMI-32
positive neurons (in two of them, the difference was sta-
tistically significant, but to a similar extent as in the case
observed in each of the other two groups of monkeys).
Overall, the unsystematic inter-hemispheric differences in
the two groups of lesioned monkeys were generally in the
same order of magnitude as those observed in the group
of intact monkeys.
Does anti-Nogo-A treatment prevent shrinkage of CS 
neurons after axotomy?
In our recent study [17], the two monkeys subjected to the
cervical lesion and treated with the control antibody
exhibited a shrinkage of their soma as a result of the CS
axotomy at cervical level. This observation is confirmed
here on a larger pool of four control-antibody treated
monkeys (Fig. 2A; blue bars): in three of the four mon-
keys, the SMI-32 positive neurons of layer V were signifi-
cantly smaller in the contralesional hemisphere than in
the ipsilesional one. In the fourth monkey (Mk-CH), no
somatic size difference was found, but in this particular
animal the quality of the SMI-32 immunostaining was
poor, which may in part explain this result. In contrast to
the majority of control antibody treated monkeys, the
intact monkeys did not show a statistically significant dif-
ference in the distribution of somatic area of layer V
pyramidal neurons between the two hemispheres (Fig.
2A; green bars). It can be concluded that CS axotomy
induced shrinkage of somatic area of the corresponding
CS neurons in the lesioned monkeys treated with the con-
trol antibody.
To address the issue whether anti-Nogo-A antibody treat-
ment, in addition to enhanced sprouting in the cervical
cord near the lesion [10,22], also prevents shrinkage of
the soma of the CS axotomized neurons, the same analy-
sis was conducted here in the group of five anti-Nogo-A
antibody treated monkeys. In all five monkeys (Fig. 2A;
red bars), the soma cross-sectional areas of SMI-32 posi-
tive layer V pyramidal neurons were significantly reduced
in the contralesional hemisphere as compared to the
ipsilesional one, indicating that the CS axotomized neu-
rons shrank. Moreover, the extent of shrinkage is generally
comparable in the anti-Nogo-A antibody treated and con-
trol antibody treated monkeys (Fig. 2C). In other words,
the anti-Nogo-A antibody treatment did not prevent or
reduce shrinkage of the soma of axotomized CS neurons.
The data of the present study are summarized in Figures
2B and 2C, where the inter-hemispheric difference (in
percent) of the number of SMI-32 positive neurons per
unit length in the layer V of M1 and of the median of their
cross-sectional soma area were plotted as a function of the
extent of the lesion, estimated in percent of the lateral spi-
nal cord. For the three groups of monkeys, there was no
systematic inter-hemispheric difference for the number of
SMI-32 positive neurons per unit length in layer V of M1
(Fig. 2B), indicating that the unilateral axotomy of the CS
tract did not produce a substantial cell loss in the contral-
esional hemisphere. Indeed, in the two groups of lesioned
monkeys, the inter-hemispheric cell number difference
was in the same range as in intact monkeys. On the other
hand, as compared to intact monkeys, the cervical hemi-
section led to a significant shrinkage of SMI-32 positive
cells in layer V of the contralesional M1, irrespective of
whether the monkey was treated with a control antibody
or an anti-Nogo-A antibody (Fig. 2C).
Discussion
Based on a substantially increased number of animals, the
present study confirms preliminary data [17] indicating
that unilateral cervical lesion is not followed by a signifi-
cant elimination of axotomized CS neurons. This conclu-
sion thus adds a new piece of evidence to the long debated
issue of whether CS neurons die after axotomy in mon-
keys. The present data are in line with previous reports
claiming that there is no extensive CS cell loss after spinal
cord lesion in monkeys [14-16]. As compared to the stud-
ies which previously addressed this question, the present
investigation is based on a specific staining of pyramidal
neurons in layer V (SMI-32), allowing better focus on the
neurons of interest (CS neurons) than for instance in Nissl
staining, as used in most cases previously. Although SMI-
32 stains pyramidal cells in layer V in general and not only
the CS neurons, the measurements conducted in the
present study are thus somewhat more directed towards
the subpopulation of CS neurons than measurementsBMC Neuroscience 2008, 9:5 http://www.biomedcentral.com/1471-2202/9/5
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Somatic size of pyramidal neurons in layer V of the motor cortex and inter-hemispheric differences Figure 2
Somatic size of pyramidal neurons in layer V of the motor cortex and inter-hemispheric differences. A: Box and 
whisker plots showing the distribution of somatic cross-sectional areas of SMI-32 positive neurons in layer V in M1 for the 
three groups of monkeys. In the box and whisker plots, the thick horizontal line in the box corresponds to the median value, 
whereas the top and bottom of the box are for the 75 and 25 percentile values respectively. The top and bottom extremities 
of the vertical lines on each side of the box are for the 90 and 10 percentile values, respectively. All but one lesioned monkey 
(red and blue bars) exhibited a significant inter-hemispheric difference of cross-sectional soma area (* = p < 0.05; ** = p < 
0.001; *** = p < 0.0001; Mann and Whitney test), whereas in the intact monkeys the difference was not statistically significant 
(n.s. = p > 0.05; Mann and Whitney test). B: Inter-hemispheric percent difference in the number of SMI-32 positive neurons per 
unit length in layer V in M1 for the same three groups of monkeys as in Figure 1C (same color code), plotted as a function of 
the lesion extent (percent of the territory corresponding to the CS and RS tracts affected by the lesion). Note that the differ-
ences are not systematic with respect to the side of the lesion in the two groups of lesioned animals (red squares and blue cir-
cles for the anti-Nogo-A and control antibody treated monkeys, respectively). In the percent comparison, 100% is for the 
number of SMI-32 positive neurons per unit length on the ipsilesional side (on the left side for the intact monkeys). The green 
triangles are for the intact monkeys. As the lesion extent could not be determined for Mk-AT (see Table 1), its corresponding 
percent value was represented by an horizontal dashed line. C: Inter-hemispheric percent difference of the median value of the 
cross-sectional soma area of SMI-32 positive neurons in layer V in M1 for the same three groups of monkeys as in panel A, 
plotted as a function of the lesion extent (percent of the territory corresponding to the CS and RS tracts affected by the 
lesion). Note that the difference is small for the intact monkeys (green symbols), but it is more prominent and systematic with 
respect to the side of the lesion for most lesioned monkeys, with considerable overlap between the two groups of lesioned 
monkeys. Same conventions as in panel B.
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conducted for instance in Nissl material, where a much
larger population of neurons would be involved. As a con-
sequence, a difference between the two hemispheres
affecting the CS neurons after a unilateral cervical lesion is
detected with more sensitivity in SMI-32 than in Nissl
material. Our measurements thus include the large
pyramidal neurons of layer V in the motor cortex, which
in the rat primary somatosensory (barrel) cortex express
intraneuronal Nogo-A [24]. Whether this is also true in
primates and relevant in the present context remains an
open question.
To investigate whether cell death occurred in layer V in the
contralesional hemisphere, we counted the number of
SMI-32 positive neurons in layer V in M1 territories of
roughly comparable size delineated on the same section
in the two hemispheres. Moreover, the data were normal-
ized with respect to the length of the layer V territory in
which the measurements were conducted. Our goal here
was not to establish the absolute number of SMI-32 posi-
tive neurons in a given cortical area but rather to compare
between the two hemispheres their relative numbers. Fur-
thermore, because the number of SMI-32 stained neurons
in the delineated territory of interest was relatively low, we
did not use a stereological probe to estimate their number,
rather we counted all of them exhibiting their nucleus.
This approach is considered as adequate for studies deal-
ing with few neurons [25-27]. For example, in a recent
morphometrical study in the hippocampus [25], the
authors used a true stereological approach to estimate the
volume of the structure of interest as well as the total abso-
lute number of neurons. In contrast, to estimate the
number of BrdU immunoreactive neurons, the authors
did not use a stereological probe because "of the low
number of BrdU-labelled cells [25]." In the present case,
the number of SMI-32 positive neurons with a visible
nucleus in the restricted zone of interest of M1 (layer V)
was also very low, thus preventing the use of stereological
probe. Furthermore, the data and their reproducibility
obtained in the five intact monkeys strongly support the
validity of the method used here to establish the number
of SMI-32 positive neurons and their cross-sectional
somatic area. Indeed, in all five intact monkeys, there was
no statistically significant inter-hemispheric difference for
their soma area. Furthermore, the number of SMI-32 pos-
itive cells did not show substantial inter-hemispheric dif-
ference in four out of five intact monkeys. In contrast, the
somatic area difference observed in the two groups of
lesioned monkeys was considerable and systematic with
respect to the side of the lesion (except in one animal, Mk-
CH). The morphometrical measurements were conducted
in the hindlimb area of M1 and not in the hand area
because the latter zone was subjected, in some animals, to
extensive intracortical microstimulation [9,28] (see also
Table 1) and, in all animals, to the injection of an antero-
grade tracer to label the CS tract [10,22]. The hand area in
M1 was thus not suitable for an optimal detection of SMI-
32 positive neurons as they may be obscured by the pres-
ence of the reaction product corresponding to the injec-
tion site. The hindlimb area, also affected by the cervical
lesion, was thus more appropriate to conduct the anatom-
ical analysis and we believe that the present data derived
from the CS neurons of the hindlimb area is very likely to
apply also to the CS neurons of the hand representation.
As shown in Figure 1C, there was no systematic inter-hem-
ispheric difference in the number of SMI-32 positive neu-
rons in the three groups of monkeys, thus supporting the
conclusion that the cervical cord hemi-section did not
provoke substantial loss of axotomized CS neurons. Con-
sidering the results in Figure 1C for the two groups of
monkeys subjected to the cervical cord hemi-section (red
and blue bar graphs), surprisingly three monkeys (Mk-AT,
Mk-AC and Mk-CS) exhibited a higher number of SMI-32
labeled neurons on the contralesional hemisphere. In the
first two monkeys, this difference was however not statis-
tically significant, reflecting in part the variability of the
method. For the third monkey (Mk-CS), the significant
difference may reflect an episodic interhemispheric differ-
ence in a minority of monkeys, as actually observed in one
intact monkey (Mk-IU in Fig. 1C) out of five intact ani-
mals. Nevertheless, the presence of some lesioned mon-
keys with more SMI-32 positive neurons on the
contralesional hemisphere reinforces the conclusion of an
absence of elimination of CS axotomized neurons after
cervical cord hemi-section. Overall, as shown in Figure
1C, the number of SMI-32 positive neurons varied across
animals, most likely reflecting individual variability both
in the number of large layer V pyramidal neurons and in
the intensity of SMI-32 staining.
The observation that there was no substantial loss of axot-
omized CS neuron after cervical hemi-section represents a
quite favorable outcome for functional recovery. Indeed,
the axons that have been severed, although they retract
some distance from the lesion [22], are still present and
potentially in position to regenerate or give rise to collat-
eral sprouting. In other words, the functional recovery
does not depend only on CS neurons spared by the lesion
or on other preserved descending tracts. In recent reports,
we demonstrated that the severed CS axons indeed can
give rise to spontaneous axonal sprouting in absence of
treatment, but only to a very limited extent [10,22]. In
contrast, an anti-Nogo-A antibody treatment substantially
enhanced CS axonal sprouting from the severed axons, as
manifested by an increase of axonal arbors rostral to the
lesion as well as axonal arbors and swellings caudal to the
lesion [10,22].BMC Neuroscience 2008, 9:5 http://www.biomedcentral.com/1471-2202/9/5
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As a result of cervical cord hemi-section, the axotomized
CS neurons in the contralesional hemisphere exhibit
shrinkage of their soma (Fig. 2A, blue bar graphs). Neuron
atrophy in response to axotomy is very well known and
widely observed, including cortical neurons. Neuronal
metabolism depends on continuous retrograde trophic
signals from the targets, which are absent or reduced in
case of axotomy. As the normal intact axonal arborization
may be much larger than the "spontaneously" newly
formed arbor of the few sprouting neurons in the control
antibody treated monkeys, the decrease of retrogradely
transported trophic signals would thus contribute to the
soma shrinkage. In the anti-Nogo-A antibody treated
monkeys, although sprouting was enhanced [22], the
quality and amount of trophic signals may be still insuffi-
cient to completely reverse the atrophy. Furthermore, the
number of CS axons that successfully sprout and re-estab-
lish an axonal arbor with contacts is not precisely known.
It is likely that only a relatively limited proportion of axot-
omized CS neurons managed to re-establish a large
axonal arbor and to obtain enough trophic signals to pre-
vent or reverse the atrophy. Increase of the somatic size of
only of few neurons would remain undetected in the
soma size distribution (Fig. 2A). Finally, the time course
has to be taken into consideration. Shortly after the lesion,
sprouting neurons are not in an atrophic state and this is
true for the initial few weeks after the injury when sprout-
ing takes place. The present morphometric measurements
were conducted in our monkeys many months post-
lesion at a time point when sprouting was completed.
However, as the newly formed axonal arbors may not be
as large as intact ones, the total amount of trophic support
they receive may still not be enough to maintain their full
soma size.
The present study provides evidence that the anti-Nogo-A
antibody treatment limits its action on the distal part of
the axotomized CS neurons, namely by enhancing axonal
sprouting close to the lesion itself, but does not prevent
changes taking place at the level of the CS cell body, at
least as far as soma size shrinkage is concerned. This con-
clusion applies to the present experimental conditions
and it cannot be excluded that soma shrinkage of axot-
omized CS neurons could have been better prevented, at
least to some extent, if the dose of the anti-Nogo-A anti-
body would have been higher or if it would have been
delivered not only near the cervical lesion but also at cor-
tical level. Indeed, although the anti-Nogo-A antibody
delivered intrathecally near the lesion site penetrates into
the CNS, the penetration was less complete in the brain
than in the spinal cord [23].
To our knowledge, the issue of CS neurons elimination
after spinal cord lesion and treatment with anti-Nogo-A
antibody has not been investigated before, even in
rodents and therefore the present observation of an
absence of anti-Nogo-A antibody treatment effect on the
shrinkage of axotomized CS neurons is original. The issue
of whether the anti-Nogo-A antibody treatment can con-
tribute to rescue cells from elimination after axotomy
could not be addressed here as there was no CS neuron
loss, even in the control antibody treated monkeys. The
absence of CS cell loss after cervical lesion contrasts with
the number of RS neurons detected in the contralesional
magnocellular red nucleus (RNm), which was up to 30%
lower than in the ipsilesional RNm [29]. However, in the
latter study conducted on the same groups of lesioned
monkeys, it was observed that the anti-Nogo-A antibody
treatment did not impact on the RS neurons, as the
number of detected RS neurons was comparable in the
anti-Nogo-A antibody and in the control antibody treated
monkeys.
Conclusion
In adult macaque monkeys, following cervical cord hemi-
section, neutralization of Nogo-A with a specific mono-
clonal antibody enhanced functional recovery [10] and
promoted sprouting of the corticospinal tract both rostral
[22] and caudal to the lesion [10,22], as compared to
monkeys treated with a control antibody. In the control
antibody treated monkeys, the corticospinal neurons in
the contralesional primary motor cortex (M1) survived to
the axotomy, but their soma shrank. The present study
tested the hypothesis that the anti-Nogo-A treatment may
prevent such soma shrinkage. We found that the anti-
Nogo-A antibody treatment did not preserve the axot-
omized corticospinal cells from soma shrinkage, indicat-
ing that the anti-Nogo-A antibody treatment affects
morphologically the axotomized corticospinal neurons
mainly at distal levels, especially the axon collateraliza-
tion in the cervical cord, and little or not at all at the level
of their soma.
Methods
The present data have been derived from a long-term pro-
tocol, described earlier in detail [9,10,17,22,28], con-
ducted on monkeys subjected to unilateral cervical cord
lesion at the C7/C8 border, in accordance with the Guide
for the Care and Use of Laboratory Animals (ISBN 0-309-
05377-3; 1996) and approved by local (Swiss) veterinary
authorities. The present study aimed at comparing three
groups of monkeys (Table 1): (i) Intact monkeys (n = 5);
(ii) Monkeys subjected to the cervical hemi-section and
treated with anti-Nogo-A antibody (n = 5); (iii) Monkeys
subjected to the cervical hemi-section and treated with a
control antibody (n = 4).
Two monoclonal antibodies (mAbs) against different sites
of the neurite inhibitor protein Nogo-A were employed
(Table 1; see also [22] for more detail on the antibodies)BMC Neuroscience 2008, 9:5 http://www.biomedcentral.com/1471-2202/9/5
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in the group of anti-Nogo-A antibody treated monkeys:
the mouse mAB 11C7 was raised against a 18 amino acid
sequence of rat Nogo-A (aa623 – 640) close to the most
inhibitory region of the Nogo-A protein [30]. The second
antibody used, mAb hNogo-A recognized the Nogo-A spe-
cific region of the human Nogo-A sequence. Both anti-
bodies identify primate Nogo-A monospecifically on
Western blots [23,30]. The antibodies were purified as
IgGs and concentrated to 3.7–10 mg/ml in PBS. In the
control antibody treated monkeys, purified IgG of a
mouse mAb directed against wheat auxin (AMS Biotech-
nology, Oxon/UK) was used as control antibody (concen-
tration: 3.7–10 mg/ml).
Briefly, the main steps of the protocol conducted on the
lesioned monkeys were the following. First, an intensive
pre-lesion training was initially performed in order to
establish a stable behavioral score in manual dexterity
tasks involving both hands [10]. A unilateral lesion was
performed at the C7/C8 border [10,17] and the antibody
(either control or anti-Nogo-A) was administered intrath-
ecally a couple of mm rostral to the lesion. The manual
dexterity tests were conducted at regular intervals for sev-
eral months post-lesion, until the animals reached a pla-
teau reflecting a stable level of functional recovery.
Anterograde tracers were injected mainly in the hand rep-
resentation of the primary motor cortex (M1) bilaterally
to label the CS tract [10,22]. The monkeys were sacrificed
under deep anesthesia and perfused transcardially with
fixatives [17]. Frozen sections comprising each of the two
hemispheres were cut in the coronal plane at a thickness
of 50 µm. The spinal cord was cut in the paralongitudinal
plane at the site of the lesion and transversally at the level
of the first cervical segments as well as of thoracic seg-
ments caudal to the lesion. The lesion was reconstructed
using SMI-32 stained material in all monkeys as previ-
ously reported [10,17] and its extent was expressed quan-
titatively by the percent of the territory delimited by two
lines starting from the central channel and extending to
the dorsal and ventral rootlets, thus covering completely
the lateral funiculus and hence the zone occupied by the
decussated CS and rubrospinal (RS) tracts. A series of
brain and spinal cord sections was treated immunocyto-
chemically with SMI-32 antibody in order to visualize in
the cerebral cortex the layers III and V pyramidal neurons
(Fig. 1B), as recently described in detail [31]. The epitope
recognised by the SMI-32 antibody lies on non-phospho-
rylated regions of neurofilament protein and is only
expressed by specific categories of neurons [32,33]. SMI-
32 positive neurons (only those exhibiting the nucleus) in
the primary motor cortex (M1) on both hemispheres were
counted under the microscope at high magnification
(400×), in a territory including layer V at the same dorso-
ventral location and defined of roughly equal length on
both hemispheres (zone delineated with a dashed line in
Fig. 1B). The typical appearance of SMI-32 positive neu-
rons in layer V of M1 was illustrated in a recent report (see
Figure 3 in [17]). At low magnification, as staining was
stronger on the ipsilesional hemisphere, the number of
SMI-32 positive neurons seems to be lower on the contral-
esional side (Fig. 1B). This is however a wrong impression
as, at higher magnification (Fig. 1D), several SMI-32 pos-
itive neurons appear on the contralesional hemisphere
(Fig. 1D): at high magnification, even lightly stained SMI-
32 positive neurons can reliably be detected. On each sec-
tion and separately for each hemisphere, the total number
of SMI-32 positive neurons was divided by the length (in
mm) of the territory in which the analysis was conducted
(line segment in Fig. 1B). Moreover, the somatic cross-sec-
tional silhouette area of these SMI-32 positive neurons in
layer V was determined, as described in detail earlier [17].
In each monkey, four to six coronal histological sections
were taken along the rostrocaudal extent of M1 (separated
by 800 µm each) in which the analysis of SMI-32 positive
neurons in layer V was conducted.
The number of SMI-32 positive neurons per unit length
(mm) obtained in a given section was averaged across the
sections analyzed in each monkey, separately for the two
hemispheres, and a standard deviation was obtained
reflecting the variability from one section to the next (Fig.
1C). This measure is proportional to the number of SMI-
32 positive neurons per volume unit. The statistical com-
parison of the number of SMI-32 positive neurons per
unit length between the two hemispheres was based on a
paired t-test for small samples applied on the four to six
sections analyzed in each monkey. A statistically signifi-
cant difference of the number of SMI-32 positive neurons
in layer V between the two hemispheres was obtained for
a t value corresponding to p <= 0.05 (df = 3 to 5 for 4 to 6
sections analyzed, respectively). The soma areas did not
follow a normal distribution (wider dispersion for large
somatic areas than small ones) and therefore they were
graphically represented in the form of box and whisker
plots (putting emphasis on the median value rather than
the mean value; Fig. 2A). Accordingly, the statistical com-
parison of soma areas of SMI-32 positive neurons
between the two hemispheres was conducted for each ani-
mal using the non-parametric unpaired Mann and Whit-
ney test (Fig. 2A), with a significance level of p <= 0.05.
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